8-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 11, 2004

Arrhythmia Research Technology, Inc.
(Exact name of issuer as specified in its charter)

Delaware	1-9731	72-0925679
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer Identification Number)
Incorporation or organization)

25 Sawyer Passway
Fitchburg, MA 01420
(Address of principal executive offices and zip code)

(978) 345-5000
(Registrant’s telephone number, including area code)

Item 5. Other Events and Regulation FD Disclosures

On August 11, 2004 the Board of Directors of Arrhythmia Research Technology, Inc. (the “Company”) declared a cash dividend. The Company issued a press release dated August 12, 2004 announcing the cash dividend, which is attached as Exhibit 99.1 to this report.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(c). Exhibits

Exhibit Number	Description
99.1	Press Release dated August 12, 2004 announcing cash dividend.
99.2	Press Release dated August 11, 2004 announcing its financial results for the 2nd quarter.

Item 12. Financial Statements

On August 11, 2004, The Company issued a press release announcing its financial results for the 2^nd quarter. The press release is attached as Exhibit 99.2 to this report.

The information set forth in this Item 12 and Exhibit 99.2 are furnished to, but shall not be deemed “filed” with the Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fitchburg, Commonwealth of Massachusetts, on the 13^th day of August 2004.

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

By: /s/ David A. Garrison

             David A. Garrison

             Chief Financial Officer

Exhibit Index

Exhibit Number	Description
99.1	Press Release dated August 12, 2004 announcing cash dividend.
99.2	Press Release dated August 11, 2004 announcing its financial results for the 2nd quarter.

EX-99

Exhibit 99.1

25 Sawyer Passway • Fitchburg, MA 01420 • (978) 345-5000

FOR IMMEDIATE RELEASE	Contact: David A. Garrison
Website: http://www.arthrt.com	(978) 345-5000
August 12, 2004

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
INCREASES CASH DIVIDEND BY 20%

Fitchburg, MA

        Arrhythmia Research Technology, Inc. (the “Company”) (AMEX: HRT) announced that its Board of Directors approved the payment of a dividend of $.06 per share to holders of record on August 27, 2004, payable on September 17, 2004.

        James E. Rouse, President and CEO, stated “The Board of Directors of the Company declared a $.06 cash dividend, an increase of 20% over the dividend paid in March 2004, as a result of the earnings in the first six months of 2004.”

        Future dividend declarations by the Board of Directors will depend upon a number of factors, including future operating results, and other investment and acquisition opportunities.

        The Company, through Micron, produces silver plated sensors and distributes metal snaps for manufacturers of disposable ECG electrodes and through Micron’s NEM division manufactures injection molded products for medical, electronics, industrial and consumer applications. The Company’s products also include proprietary signal-averaging electrocardiographic (SAECG) software used in the detection and treatment of potentially lethal heart arrhythmias.

        Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks, changing economic conditions in developing countries, and an inability to arrange additional debt or equity financing. More information about factors that potentially could affect the Company’s financial results is included in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2003.

EX-99

Exhibit 99.2

25 Sawyer Passway • Fitchburg, MA 01420 • (978) 345-5000

FOR IMMEDIATE RELEASE	Contact: David A. Garrison
Website: http://www.arthrt.com	(978) 345-5000
August 11, 2004

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.ANNOUNCES
RESULTS FOR THE SECOND QUARTER 2004

Fitchburg, MA

        Arrhythmia Research Technology, Inc. (the “Company”) (AMEX: HRT) and its wholly owned subsidiary Micron Products, Inc. (“Micron”) reported total revenue of $3,114,000 and net income of $440,000 for the quarter ended June 30, 2004 compared to total revenue of $1,940,000 and net income of $285,000 for the same quarter of 2003. Net income per share for the three months ended June 30, 2004 increased to $.17 per share from $.11 per share for the same period in 2003.

        Total revenue increased by 61% in the quarter ending June 30, 2004 as compared to the same period in 2003. The net income increased by 54% while the earnings per share increased by 55% for the quarter ending June 30, 2004 over the same period in 2003.

        Total revenue for the first six months of 2004 was $5,266,000 and net income amounted to $759,000 compared to total revenue of $3,815,000 and net income of $564,000 for the same period in 2003. Basic net income per share for the six months ended June 30, 2004 increased to $0.29 per share from $0.21 per share for the same period in 2003.

        James E. Rouse, the Company’s President and CEO commented, “On May 7, 2004, Micron Products completed the acquisition of New England Molders (NEM), a custom thermoplastic injection molder specializing in the manufacture of intricately designed products primarily for medical, electronics, industrial and consumer applications. Despite being a part of the organization for less than two months in the second quarter, the newly acquired division contributed approximately 32% of the revenue increase or approximately $378,000. We expect the NEM division of Micron to increase its revenue and net income contribution in the future as we take advantage of the synergies provided by merging the two manufacturing facilities into one by the beginning of the fourth quarter. The balance of the increase in revenue is attributable to a 40% increase in Micron’s unit volume sales, primarily to existing customers. Our higher earnings are attributable to the increase in revenue and our continuing capital investment in tools and equipment aimed at reducing the cost to manufacture our products. Additionally, our effective tax rate increased due to a better than expected utilization of deferred tax assets in 2003. The provision for income taxes increased 103% or $223,000 for the first six months of 2004 as compared to 2004. Our pretax income for the six months ending June 30, 2004 was $1,198,000 as compared to $780,000 for the same period in 2003, a 54% increase.”

        The Company, through Micron, produces silver plated sensors and distributes metal snaps for manufacturers of disposable ECG electrodes and through Micron’s NEM division manufactures injection molded products for medical, electronics, industrial and consumer applications. The Company’s products also include proprietary signal-averaging electrocardiographic (SAECG) software used in the detection and treatment of potentially lethal heart arrhythmias.

        Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks, changing economic conditions in developing countries, and an inability to arrange additional debt or equity financing. More information about factors that potentially could affect the Company’s financial results is included in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2003.